Onglyza® Pancreatic Cancer Risk

Approved by the U.S. Food and Drug Administration (FDA) in 2009, Onglyza® (saxagliptin) belongs to a class of Type 2 diabetes drugs called incretin mimetics, also known as GLP-1 therapies.

Used along with a diet and exercise, these drugs can help patients lower their blood sugar and regulate insulin levels. But incretin mimetics have recently come under increased scrutiny after researchers suggested the drugs may increase the risk of pancreatic cancer, which can be especially dangerous and difficult to treat because it is usually not diagnosed until its later stages.

If you or someone you love took Onglyza and were diagnosed with pancreatic cancer, you may be eligible for compensation. At Cory Watson Attorneys, our drug injury attorneys hold drug companies accountable for the harm they cause, and we’re here to protect your rights. Call (877) 562-0000 or fill out our free initial consultation form to get help now.

You May Have an Onglyza® Pancreatic Cancer Lawsuit

You’re not alone if you or someone you love were diagnosed with pancreatic cancer after taking Onglyza. Your time to file a lawsuit is limited. The 24/7 legal staff at Cory Watson Attorneys is ready to help now—just call (877) 562-0000 or complete a free initial consultation form to get started.

Onglyza® is a registered trademark of AstraZeneca PLC, and is used here only to identify the product in question.

This law firm is not associated with, sponsored by, or affiliated with AstraZeneca PLC, the American Diabetes Association, or the U.S. Food and Drug Administration.